G2 Investment Partners Management Decreased Truecar (TRUE) Stake; Shorts at Crispr Therapeutics AG (CRSP) Lowered By 13.3%

January 14, 2018 - By Stephen Andrade

G2 Investment Partners Management Llc decreased Truecar Inc (TRUE) stake by 60.43% reported in 2017Q3 SEC filing. G2 Investment Partners Management Llc sold 154,943 shares as Truecar Inc (TRUE)’s stock rose 21.77%. The G2 Investment Partners Management Llc holds 101,472 shares with $1.60M value, down from 256,415 last quarter. Truecar Inc now has $1.17B valuation. The stock decreased 3.61% or $0.44 during the last trading session, reaching $11.74. About 1.68M shares traded. TrueCar, Inc. (NASDAQ:TRUE) has risen 161.73% since January 14, 2017 and is uptrending. It has outperformed by 145.03% the S&P500.

Crispr Therapeutics AG (NASDAQ:CRSP) had a decrease of 13.3% in short interest. CRSP’s SI was 948,100 shares in January as released by FINRA. Its down 13.3% from 1.09M shares previously. With 356,400 avg volume, 3 days are for Crispr Therapeutics AG (NASDAQ:CRSP)’s short sellers to cover CRSP’s short positions. The SI to Crispr Therapeutics AG’s float is 11.63%. The stock increased 0.28% or $0.08 during the last trading session, reaching $28.52. About 897,001 shares traded or 100.21% up from the average. CRISPR Therapeutics AG (NASDAQ:CRSP) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.




CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland. The company has market cap of $1.17 billion. The CRISPR/Cas9 technology allows for changes to genomic DNA. It currently has negative earnings. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies.

Among 5 analysts covering CRISPR Therapeutics (NASDAQ:CRSP), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. CRISPR Therapeutics had 5 analyst reports since November 14, 2016 according to SRatingsIntel. Barclays Capital initiated the shares of CRSP in report on Monday, November 14 with “Overweight” rating. The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) has “Buy” rating given on Monday, November 14 by Guggenheim. The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) earned “Neutral” rating by Citigroup on Tuesday, November 15. Piper Jaffray initiated CRISPR Therapeutics AG (NASDAQ:CRSP) on Monday, November 14 with “Overweight” rating.

Analysts await TrueCar, Inc. (NASDAQ:TRUE) to report earnings on February, 15. They expect $-0.08 earnings per share, 0.00% or $0.00 from last year’s $-0.08 per share. After $-0.08 actual earnings per share reported by TrueCar, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 2.16 in Q3 2017. Its up 0.25, from 1.91 in 2017Q2. It increased, as 24 investors sold TRUE shares while 19 reduced holdings. 35 funds opened positions while 58 raised stakes. 82.38 million shares or 7.55% more from 76.60 million shares in 2017Q2 were reported. Royal Comml Bank Of Canada holds 0% of its portfolio in TrueCar, Inc. (NASDAQ:TRUE) for 30,118 shares. First Mercantile Tru has 0.06% invested in TrueCar, Inc. (NASDAQ:TRUE). Quantbot Technology LP reported 53,386 shares. Chicago Equity Prtnrs Ltd Liability Corp has 0.01% invested in TrueCar, Inc. (NASDAQ:TRUE). Schwab Charles Investment Inc has invested 0% in TrueCar, Inc. (NASDAQ:TRUE). Arrowstreet Cap Ltd Partnership, Massachusetts-based fund reported 35,300 shares. Par Cap, a Massachusetts-based fund reported 4.83M shares. Point72 Asia (Hong Kong) Limited has invested 0.01% of its portfolio in TrueCar, Inc. (NASDAQ:TRUE). Secor Capital LP owns 41,868 shares or 0.06% of their US portfolio. Blackrock owns 4.36M shares. California State Teachers Retirement Sys holds 0% of its portfolio in TrueCar, Inc. (NASDAQ:TRUE) for 110,991 shares. Columbus Circle has 0.1% invested in TrueCar, Inc. (NASDAQ:TRUE) for 379,234 shares. Schroder Investment Mgmt Group stated it has 0% in TrueCar, Inc. (NASDAQ:TRUE). 18,294 are held by Cim Invest Mangement Inc. Swiss Fincl Bank holds 0% or 116,500 shares.

Among 14 analysts covering TrueCar (NASDAQ:TRUE), 7 have Buy rating, 1 Sell and 6 Hold. Therefore 50% are positive. TrueCar had 36 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by FBR Capital with “Buy” on Tuesday, November 7. The firm earned “Neutral” rating on Wednesday, October 11 by Goldman Sachs. Cowen & Co maintained TrueCar, Inc. (NASDAQ:TRUE) on Wednesday, August 16 with “Hold” rating. On Tuesday, April 5 the stock rating was initiated by Topeka Capital Markets with “Hold”. The stock of TrueCar, Inc. (NASDAQ:TRUE) has “Buy” rating given on Friday, November 4 by Loop Capital. The firm has “Neutral” rating given on Friday, July 24 by JP Morgan. RBC Capital Markets maintained the shares of TRUE in report on Friday, February 19 with “Sector Perform” rating. As per Thursday, August 11, the company rating was initiated by Loop Capital. The firm earned “Buy” rating on Friday, November 4 by Craig Hallum. The rating was maintained by B Riley with “Sell” on Friday, August 7.

G2 Investment Partners Management Llc increased Chegg Inc (NYSE:CHGG) stake by 61,700 shares to 393,446 valued at $5.84M in 2017Q3. It also upped Health Ins Innovations Inc (NASDAQ:HIIQ) stake by 31,125 shares and now owns 69,946 shares. Quotient Technology Inc was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts